Formulary 101: The Medicare Program Hosts A Cash Course In Therapeutic Alternatives
This article was originally published in RPM Report
CMS and the Medicare private drug plans are using Medicare enrollment to teach seniors -- and their adult advisors -- about the cost savings from therapeutic interchange. Training patients to look for cost savings and to discuss costs with doctors is clearly a secondary objective of the Medicare enrollment process. The Medicare plan finder website and private plan sites carry frequent messages to alert beneficiaries cost savings. Pfizer responds with consumer-based pricing for Lipitor.
You may also be interested in...
It's not often than any industry group voluntarily agrees to give up $80 billion in future revenues, but that's what the Pharmaceutical Research & Manufacturers of America is pledging to do to in the context of the health care reform debate. There are a lot of details to work out, but this is a case where what is important is not what PhRMA is giving-but what it gets.
The key part of PhRMA's deal with the Finance Committee is a double win for industry: assuring that closing the donut hole will be part of reform, and that PhRMA will get credit for a big part of the savings.
Bayer is CMS to add multiple sclerosis to the list of drug classes protected from formulary restrictions under the Medicare Part D prescription drug program. The first request to broaden the list of protected classes won't be the last.